BAX

Dollar General Options Activity: Dollar General Corp (DG) has seen a trading volume of 23,831 options contracts today, representing about 2.4 million shares, with notable activity in the $92 strike call option expiring April 04, 2025.

Super Micro Computer Options Activity: Super Micro Computer Inc (SMCI) has recorded a significant options volume of 253,757 contracts today, equating to approximately 25.4 million shares, highlighted by high trading in the $30 strike put option expiring April 04, 2025.

Annual Meeting Details: Baxter International Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 6, 2025, at 9 a.m. Central Time, with online access starting at 8:45 a.m. Stockholders are encouraged to vote their shares prior to the meeting and can submit questions before or during the event.

Participation Information: Stockholders can attend the meeting by logging in with their control number, while guests can listen in without the ability to ask questions or vote. Voting options are available both before and during the meeting for those who have not yet cast their votes.

Company Overview: Baxter International Inc. is a large-cap medical instrument manufacturer with a market cap of $17.2 billion, operating in over 100 countries and focusing on healthcare products for chronic and acute conditions.

Stock Performance: Despite a recent surge following better-than-expected Q4 results, Baxter's stock has underperformed the broader market over the past year, with analysts rating it as a "Moderate Buy" and projecting a price target suggesting a potential upside.

Dividend Predictability: Dividend amounts are unpredictable and fluctuate based on a company's profitability, with Baxter International Inc serving as an example for assessing future dividend expectations.

Author's Perspective: The opinions expressed in the article reflect the author's views and may not represent those of Nasdaq, Inc.

Company Overview: Becton, Dickinson, and Company (BDX) is a major medical technology firm with a market capitalization of $64.9 billion, offering products that enhance healthcare through improved medication management and diagnostic solutions, despite recent stock performance challenges.

Stock Performance and Analyst Outlook: Following a strong Q1 earnings report, BDX shares fell 7.3% due to macroeconomic concerns, yet analysts maintain a "Strong Buy" consensus with a mean price target of $273.47, indicating optimism for future growth.

Event Announcement: Baxter International Inc. will present at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 1:00 PM ET.

Webcast Access: The live webcast of the presentation can be accessed through Baxter's investor relations website.

Investor Sentiment: After two years of strong performance, U.S. stocks are facing investor discontent due to policy uncertainty, particularly regarding tariffs and economic slowdown expectations.

Market Decline: As a result of these concerns, 77% of the S&P 500 companies are projected to experience declines in 2025, according to recent price data from FactSet.

Analyst Ratings Changes: Top Wall Street analysts have adjusted their price targets and ratings for several companies, including Baxter International, Costco, SLM Corporation, and XPeng Inc, with some receiving upgrades while others faced downgrades.

Stock Performance Overview: The article highlights the closing prices of various stocks on Friday, noting significant changes in target prices and analyst recommendations, reflecting a mixed outlook across different sectors.

Analyst Ratings: Barclays analyst Matt Miksic has maintained a Buy rating on Baxter International with a price target of $41.00, while Goldman Sachs also issued a Buy rating; however, Morgan Stanley has a Sell rating on the stock.

Stock Performance: Baxter International's shares closed at $36.57, with a one-year high of $43.99 and a low of $28.34, and the company has an average trading volume of 4.98 million shares.

USMCA Exemption Announcement: President Trump announced a one-month exemption for USMCA-compliant goods, which is seen as beneficial for medical technology companies with significant exposure to Mexico, such as Conmed, Teleflex, and Medtronic.

Investment Insights: The article highlights the potential for strong investment opportunities in stocks related to medical technology, suggesting that analysts are providing positive ratings on certain stocks.

Event Announcement: Baxter International Inc. will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 1:10 PM ET.

Webcast Access: A live webcast of the event can be accessed through Baxter's investor relations website.

Goldman Sachs' Conviction List: Goldman Sachs has added three new stocks to its conviction list, including Baxter, Deere, and Viper Energy, highlighting their potential for turnaround and growth despite recent challenges in performance.

Stock Performance Insights: Analysts from Goldman Sachs are optimistic about Baxter's focus on profit optimization, Deere's expected earnings recovery as it nears a cyclical bottom, and Viper Energy's unique business model in the oil and gas sector.

Goldman Sachs Update: Analysts at Goldman Sachs have added Baxter (BAX) to their US Conviction List, anticipating a turnaround in the company's shares due to stable revenue growth, significant operating margin expansion, and increased free cash flow. They maintain a Buy rating with a price target of $42.

Investment Insights: The article highlights the potential for maximizing investment portfolios by leveraging strong buy ratings from top analysts, suggesting tools like TipRanks’ Stock Screener for identifying promising stocks.

Stock Performance: West Pharmaceutical Services Inc. shares increased by 4.39% to $232.34, marking the second consecutive day of gains for the stock.

Market Overview: The overall stock market had a positive trading session, with the S&P 500 rising 1.59% and the Dow Jones Industrial Average increasing by 1.39%.

Upcoming Ex-Dividend Dates: Baxter International Inc, Bank of Hawaii Corp, and Evercore Inc Class A will trade ex-dividend on 2/28/25, with respective dividends of $0.17, $0.70, and $0.80, leading to expected price drops of approximately 0.47%, 0.99%, and 0.33% respectively.

Dividend Stability and Yields: Historical dividend performance suggests varying stability for these companies, with estimated annual yields of 1.89% for Baxter, 3.95% for Bank of Hawaii, and 1.33% for Evercore, while Evercore is close to becoming a "Dividend Aristocrat" with over 17 years of increases.

Baxter International Presentation: Baxter International Inc. will present at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, with CFO Joel Grade speaking at 1:00 p.m. Eastern Time. The presentation will be available for live streaming and replay until September 8, 2025.

About Baxter: Baxter has been a leader in medical technology for over 90 years, providing essential healthcare products and solutions globally, impacting millions of patients and healthcare providers across various settings.

Baxter International Inc. Analysis: Baxter International Inc. (BAX) receives a high rating of 75% from Validea's Shareholder Yield Investor model, indicating strong fundamentals and valuation in the Medical Equipment & Supplies industry, particularly for companies returning cash to shareholders.

Meb Faber's Investment Strategy: Meb Faber, founder of Cambria Investments, emphasizes shareholder yield through dividends, buybacks, and debt paydown, which forms the basis of his investment strategies and research on creating value for shareholders.

Baxter International Filing: Baxter International has filed for an automatic mixed securities shelf, indicating potential future financing activities.

Financial Performance and Growth Outlook: The company is targeting a revenue growth of 5%-6% by 2025, driven by the success of its Novum IQ pump and operational recovery, with recent Q4 results exceeding guidance.

UnitedHealth Ratings: Analysts maintain a Strong Buy consensus on UnitedHealth (UNH), with Barclays setting a price target of $642, indicating a potential upside of 46.2% from its current price of $466.42.

Baxter International Ratings: Baxter International (BAX) holds a Hold rating from analysts, with a price target of $40, suggesting a modest upside of 13.4% from its recent closing price of $33.82.

Analyst Ratings on Baxter International: Vijay Kumar from Evercore ISI has maintained a Buy rating on Baxter International with a price target of $44.00, while Barclays also issued a Buy rating, and Bank of America Securities reiterated a Hold rating.

Company Performance Metrics: Baxter International has a market cap of $17.27 billion and a P/E ratio of -26.59, indicating ongoing financial assessments amidst varying analyst opinions.